[1] |
Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families[J]. Pigment Cell Res, 2003,16(3):208⁃214. doi: 10.1034/j.1600⁃0749.2003.00032.x.
|
[2] |
Bhandarkar SS, Kundu RV. Quality⁃of⁃life issues in vitiligo[J]. Dermatol Clin, 2012,30(2):255⁃268, viii. doi: 10.1016/j.det.2011. 11.013.
|
[3] |
Yaghoobi R, Omidian M, Bagherani N. Vitiligo: a review of the published work[J]. J Dermatol, 2011,38(5):419⁃431. doi: 10. 1111/j.1346⁃8138.2010.01139.x.
|
[4] |
许爱娥. 白癜风发病机制及治疗靶点的研究现状[J]. 中华皮肤科杂志, 2016,49(6):377⁃379. doi: 10.3760/cma.j.issn.0412⁃4030.2016.06.001.
|
[5] |
李春英, 李舒丽. 白癜风发病机制研究热点解析[J]. 中华皮肤科杂志, 2019,52(9):593⁃597. doi: 10.3760/cma.j.issn.0412⁃4030.2019.09.001.
|
[6] |
Silverberg JI, Silverberg NB. Clinical features of vitiligo associated with comorbid autoimmune disease: a prospective survey[J]. J Am Acad Dermatol, 2013,69(5):824⁃826. doi: 10. 1016/j.jaad.2013.04.050.
|
[7] |
Kanwar AJ, Mahajan R, Parsad D. Effect of age at onset on disease characteristics in vitiligo[J]. J Cutan Med Surg, 2013,17(4):253⁃258. doi: 10.2310/7750.2013.12075.
|
[8] |
Speeckaert R, van Geel N. Distribution patterns in generalized vitiligo[J]. J Eur Acad Dermatol Venereol, 2014,28(6):755⁃762. doi: 10.1111/jdv.12171.
|
[9] |
van Geel N, Speeckaert R, De Wolf J, et al. Clinical significance of Koebner phenomenon in vitiligo[J]. Br J Dermatol, 2012,167(5):1017⁃1024. doi: 10.1111/j.1365⁃2133.2012.11158.x.
|
[10] |
van Geel N, Speeckaert M, Brochez L, et al. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases[J]. J Eur Acad Dermatol Venereol, 2014,28(6):741⁃746. doi: 10.1111/jdv.12169.
|
[11] |
Spritz RA. Six decades of vitiligo genetics: genome⁃wide studies provide insights into autoimmune pathogenesis[J]. J Invest Dermatol, 2012,132(2):268⁃273. doi: 10.1038/jid.2011.321.
|
[12] |
LaBerge GS, Bennett DC, Fain PR, et al. PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not[J]. J Invest Dermatol, 2008,128(7):1757⁃1762. doi: 10.1038/sj.jid. 5701233.
|
[13] |
D′Osualdo A, Reed JC. NLRP1, a regulator of innate immunity associated with vitiligo[J]. Pigment Cell Melanoma Res, 2012,25(1):5⁃8. doi: 10.1111/j.1755⁃148X.2011.00942.x.
|
[14] |
Birlea SA, Laberge GS, Procopciuc LM, et al. CTLA4 and generalized vitiligo: two genetic association studies and a meta⁃analysis of published data[J]. Pigment Cell Melanoma Res, 2009,22(2):230⁃234. doi: 10.1111/j.1755⁃148X.2009.00543.x.
|
[15] |
Carvalho CL, Ortigosa LC. Segmental vitiligo after infliximab use for rheumatoid arthritis⁃⁃a case report[J]. An Bras Dermatol, 2014,89(1):154⁃156. doi: 10.1590/abd1806⁃4841.20142887.
|
[16] |
Maruthappu T, Leandro M, Morris SD. Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab[J]. Dermatol Ther, 2013,26(4):370⁃372. doi: 10. 1111/dth.12002.
|
[17] |
Karelson M, Silm H, Salum T, et al. Differences between familial and sporadic cases of vitiligo[J]. J Eur Acad Dermatol Venereol, 2012,26(7):915⁃918. doi: 10.1111/j.1468⁃3083.2011.04131.x.
|